Easy Access to E-cigarettes for Children in Melbourne, Australia

Regulations by 2FIRSTS.ai
Dec.01.2023
Easy Access to E-cigarettes for Children in Melbourne, Australia
A new study reveals that children in western Melbourne can easily purchase e-cigarettes illegally, raising concerns about underage access.

According to a report by the Australian Broadcasting Corporation (ABC) on November 30, a new study has found that children in the western suburbs of Melbourne, Australia, can easily purchase e-cigarettes illegally.

Easy Access to E-cigarettes for Children in Melbourne, Australia
Type analysis | Image source: ABC

 

A report by the Western Public Health Unit (WPHU) has revealed that the majority of e-cigarette shops are located within a distance of less than 750 meters from schools. Third-party retailers, including both cigarette and e-cigarette stores, account for one-third of all e-cigarette sales outlets, while the rest are comprised of milk bars, grocery stores, convenience stores, cafes, and non-food retailers.

 

WPHU has discovered 59 stores in Brimbank selling e-cigarettes. The average price of e-cigarettes is $25, with prices ranging from $10 to $45.

 

The next phase of the Australian government's crackdown on e-cigarettes is set to begin on January 1st, when the ban on importing disposable e-cigarettes will come into effect. Dr. Romanes, Director of the WPHU, expressed his hope that this will be a turning point.

 

He stated, "At some point next year, there will be a comprehensive ban on the commercial sale of non-prescription e-cigarettes, marking a highly significant moment.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Bill 221 (SB 221), which seeks to regulate the retail sale of nicotine products, has passed the Senate Health and Human Services Committee with a unanimous 7–0 recommendation. The bill was significantly amended, expanding from three to nine pages and shifting its focus from vapor products alone to all nicotine products.
Regulations
Feb.22
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
South Dakota Legislature Approves Two Nicotine Licensing Bills Pending Governor’s Decision
South Dakota Legislature Approves Two Nicotine Licensing Bills Pending Governor’s Decision
The South Dakota Legislature gave final approval on Tuesday to two proposals requiring state licenses for businesses that sell nicotine products. Under the bills, wholesalers, distributors and retailers of nicotine products in the state would need to be licensed by the government.
Mar.12 by 2FIRSTS.ai
Fontem Sues FDA Over Refusal-to-File Decision for Nicotine Pouch PMTAs
Fontem Sues FDA Over Refusal-to-File Decision for Nicotine Pouch PMTAs
According to a complaint filed on March 17 in the U.S. District Court for the Northern District of Texas, Fontem US, LLC and Texas retailer OM Investment, LLC sued the Food and Drug Administration and the Department of Health and Human Services over FDA’s refusal-to-file decision for certain Zone nicotine pouch PMTAs.
Mar.19 by 2FIRSTS.ai
Bangladesh High Court rule targets vape-ban clause; fines up to about $1,635 cited
Bangladesh High Court rule targets vape-ban clause; fines up to about $1,635 cited
Bangladesh’s High Court issued a rule asking why Section 6(G) of the Smoking and Tobacco Products Usage (Control) Act, 2005 — which bans the import, supply and sale of vapes and e-cigarettes — should not be declared unconstitutional and illegal.
Mar.02 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24